Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic pancreatic islet cells (University of Nebraska) refer to an investigational cell therapy for the treatment of Type 1 Diabetes Mellitus. The therapy involves the isolation of islets of Langerhans from a cadaveric donor pancreas, which is preserved using the Two-Layer preservation method (TLM) to maintain tissue viability via oxygenation with perfluorocarbon. The purified islets are then infused into the recipient's portal vein. Once engrafted in the liver, these cells function as a biological replacement for destroyed beta cells, sensing blood glucose levels and secreting insulin to restore glycemic control. The University of Nebraska Medical Center's protocol specifically utilized a steroid-free immunosuppressive regimen to enhance islet survival and function, aiming to achieve insulin independence and reduce the incidence of severe hypoglycemic events.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic pancreatic islet cells (University of Nebraska Medical Center).